These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37981082)

  • 1. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
    Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
    Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L; Xu M; Jiang X; Sun X
    Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.
    Takahashi T; Sonobe M; Kobayashi M; Yoshizawa A; Menju T; Nakayama E; Mino N; Iwakiri S; Sato K; Miyahara R; Okubo K; Manabe T; Date H
    Ann Surg Oncol; 2010 Mar; 17(3):889-97. PubMed ID: 20183914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
    J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
    Mitiushkina NV; Romanko AA; Preobrazhenskaya EV; Tiurin VI; Ermachenkova TI; Martianov AS; Mulkidjan RS; Sokolova TN; Kholmatov MM; Bizin IV; Ivantsov AO; Yatsuk OS; Zaitseva OA; Iyevleva AG; Kuligina ES; Imyanitov EN
    Cancer Med; 2022 Sep; 11(17):3226-3237. PubMed ID: 35322575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.
    Liu Q; Huang Q; Yu Z; Wu H
    Clin Respir J; 2022 Mar; 16(3):216-225. PubMed ID: 35081265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Zhou X; Shou J; Sheng J; Xu C; Ren S; Cai X; Chu Q; Wang W; Zhen Q; Zhou Y; Li W; Pan H; Li H; Sun T; Cheng H; Wang H; Lou F; Rao C; Cao S; Pan H; Fang Y
    Cancer Sci; 2019 Oct; 110(10):3382-3390. PubMed ID: 31444835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell block-based RNA next generation sequencing for detection of gene fusions in lung adenocarcinoma: An institutional experience.
    Wei S; Talarchek JN; Huang M; Gong Y; Du F; Ehya H; Flieder DB; Patchefsky AS; Wasik MA; Pei J
    Cytopathology; 2023 Jan; 34(1):28-34. PubMed ID: 36062384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
    Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
    J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Validation of
    Kim SW; DO SI; Na K
    Anticancer Res; 2021 Sep; 41(9):4609-4617. PubMed ID: 34475089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
    Zhu VW; Klempner SJ; Ou SI
    Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers.
    Tan AC; Itchins M; Khasraw M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y; Zhang Y; Li Y; Hu H; Wang L; Li H; Wang R; Ye T; Luo X; Zhang Y; Li B; Cai D; Shen L; Sun Y; Chen H
    Lung Cancer; 2014 May; 84(2):121-6. PubMed ID: 24629636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
    Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
    Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
    Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
    Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.